Abstract
The selection of appropriate pharmacologic therapy for any disease requires a careful assessment of benefit and risk. In the case of type 2 diabetes, this decision typically balances the benefits accrued from improved glycemic control with the risks inherent in glucose-lowering medications. This review is intended to assist therapeutic decision-making by carefully assessing the potential benefit from improved metabolic control relative to the potential risks of a wide array of currently prescribed glucose-lowering agents. Wherever possible, risks and benefits have been expressed in terms of absolute rates (events per 1000 patient-years) to facilitate cross-study comparisons. The review incorporates data from new studies (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation, Action to Control Cardiovascular Risk in Diabetes, and the Veterans Affairs Diabetes Trial), as well as safety issues associated with newer glucose-lowering medications. © 2010 Elsevier Inc. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 374.e9-374.e18 |
| Number of pages | 10 |
| Journal | American Journal of Medicine |
| Volume | 123 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2010 |
Keywords
- age distribution
- blood glucose
- type 2 diabetes mellitus
- humans
- hypoglycemic agents
- risk factors